Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
126 hedge funds and large institutions have $919M invested in Audentes Therapeutics, Inc in 2018 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 28 reducing their positions, and 11 closing their positions.
135% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $446K
111% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 28
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
11% more funds holding
Funds holding: 114 → 126 (+12)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
36% less capital invested
Capital invested by funds: $1.43B → $919M (-$511M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$42.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$37.9M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$19.9M |
| 4 |
Millennium Management
New York
|
+$15.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$15.9M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$12.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$11.4M |
BOLD Hedge Fund Activity: Q4 2018 in Review
126 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q4 2018, worth a combined $919M — down 36% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BOLD positions and 11 closed out — a net gain of 12 holders — while 59 added to existing stakes and 28 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $42.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $36.7M.
- 126 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q4 2018, up from 114 in Q3 2018.
- Funds reported $919M of Audentes Therapeutics, Inc stock for Q4 2018, down 36% quarter-over-quarter.
- 23 funds opened new Audentes Therapeutics, Inc positions in Q4 2018 and 11 closed out, a net change of +12 holders.
- The largest Audentes Therapeutics, Inc buyer in Q4 2018 was Great Point Partners, an estimated $42.8M added.
- The largest Audentes Therapeutics, Inc seller in Q4 2018 was T. Rowe Price Associates, an estimated $36.7M sold.
Based on aggregated 13F filings for Q4 2018.